Clinical trial
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal…
NCT00324714 · ETOP IBCSG Partners Foundation, Other · Withdrawn
Key facts
| NCT number | NCT00324714 |
|---|---|
| Title | Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS |
| Official title | A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women |
| Lead sponsor | ETOP IBCSG Partners Foundation, Other |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Osteoporosis |
| Intervention type | Drug, Other |
| Interventions | risedronate sodium, diagnostic laboratory biomarker analysis |
| Enrollment | 0 |
| Start date | Feb 1, 2003 |
| First posted | May 11, 2006 |
| Last update posted | Nov 29, 2012 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: